ArticleDrug testing and analysis2025
Detection of Anabolic Androgenic Steroids and Steroid Esters-Comparing Dried Blood Spots Collection Devices and Urine Samples.
Article in Drug testing and analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Detection of Testosterone Esters in Urine: Evidence of Trace-Level Detectability in Doping Control Samples.Drug testing and analysis · 2026Article
- The Evolution of Precision Anti-Doping From UGT2B17 Polymorphism Insights to Integrated Detection Frameworks.Drug testing and analysis · 2026Review
- Detection of Anabolic Androgenic Steroids and Steroid Esters-Comparing Dried Blood Spots Collection Devices and Urine Samples.Drug testing and analysis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dried blood spots (DBS) have emerged as a promising complement, and in some settings, an alternative, to urine for anabolic androgenic steroid (AAS) testing, offering advantages such as minimal invasiveness, simplified storage, and transportation. This study evaluated two DBS collection devices-cellulose-based Capitainer-B50 and polymer-based Tasso-M20-and compared results with traditional urine analysis. Ten self-reported AAS users were recruited and provided matched urine and DBS samples. High agreement between the two DBS devices was observed, although Capitainer-B50 showed a slightly greater detection rate, likely due to a higher sample volume (50 μL vs. 17.5 μL) improved analyte recovery, and lower background noise. Notably, DBS enabled detection of testosterone use in all 10 participants, while urine testing missed two cases with naturally low urinary testosterone/epitestosterone (T/E) ratios (most likely UGT2B17 del/del carriers). Moreover, the differentiation between prescribed and illicit use of testosterone esters was also possible in DBS, but not in urine testing, while nandrolone detection in DBS was limited at low concentrations. The findings support DBS as a sensitive and practical tool for AAS detection and provide critical advantages in detecting doping with testosterone esters in individuals with prescribed testosterone therapy and in UGT2B17 deletion carriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.